Victoza

Victoza

liraglutide

Manufacturer:

Novo Nordisk

Distributor:

Novo Nordisk
Concise Prescribing Info
Contents
Liraglutide
Indications/Uses
Adults w/ type 2 DM in monotherapy & in combination w/ oral glucose-lowering medicinal products &/or basal insulin when these, together w/ diet & exercise do not provide adequate glycemic control.
Dosage/Direction for Use
SC Initially 0.6 mg daily, increased to 1.2 mg after at least 1 wk. Max daily dose: 1.8 mg.
Administration
May be taken with or without food: Preferably administered at the same time each day.
Contraindications
Special Precautions
Should not be used in patients w/ type 1 DM or for the treatment of diabetic ketoacidosis. Not a substitute for insulin. Do not administer by IV or IM. Patients w/ CHF NYHA class I-IV; inflammatory bowel disease & diabetic gastroparesis; preexisting thyroid disease; history of pancreatitis. Severe renal impairment including end-stage renal disease; mild, moderate or severe hepatic impairment. Use of GLP-1 analogues has been associated w/ risk of acute pancreatitis; signs & symptoms of dehydration, including renal impairment & acute renal failure; increased risk of hypoglycemia when used in combination w/ sulfonylurea or a basal insulin. May affect ability to drive or operate machinery due to risk of hypoglycemia especially when used in combination w/ a sulfonylurea or basal insulin. Should not be used during pregnancy & lactation. Childn & adolescent  <18 yr. Elderly ≥75 yr.
Adverse Reactions
Nausea, diarrhea, vomiting, constipation, toothache, abdominal pain/distension/discomfort, dyspepsia, gastritis, flatulence, GERD, pancreatitis; headache, dizziness; hypoglycemia, anorexia, decreased appetite; nasopharyngitis, bronchitis; increased heart rate; fatigue, malaise; renal impairment, acute renal failure; urticaria, rash, pruritus; anaphylactic reaction; inj site reactions.
Drug Interactions
Frequent monitoring of INR w/ warfarin or other coumarin derivatives. May decrease Cmax & delay median tmax of paracetamol, atorvastatin & OCs (eg, ethinylestradiol, levonorgestrel). May increase Cmax of griseofulvin. Reduced AUC, decreased Cmax & delayed tmax of digoxin & lisinopril.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BJ02 - liraglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.
Presentation/Packing
Form
Victoza soln for inj 6 mg/mL
Packing/Price
3 mL x 2 × 1's (P9,632/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in